2-Isopropyl-4-aminopyrazolo<3,4-d>pyrimidin | 2056-66-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡唑并嘧啶类
• 英文名称: 2-Isopropyl-4-aminopyrazolo<3,4-d>pyrimidin
• 英文别名: 2-isopropyl-2H-pyrazolo[3,4-d]pyrimidin-4-ylamine；2-isopropyl-4-amino-pyrazolo[3,4-d]pyrimidine；2-(Propan-2-yl)-2h-pyrazolo[3,4-d]pyrimidin-4-amine；2-propan-2-ylpyrazolo[3,4-d]pyrimidin-4-amine
• CAS: 2056-66-8
• 化学式: C₈H₁₁N₅
• 分子量: 177.209
• InChiKey: PERFWRNKWQXMCO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  69.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  3-氨基-1-异丙基-1H-吡唑-4-甲腈 、 formamide 生成 2-Isopropyl-4-aminopyrazolo<3,4-d>pyrimidin
  参考文献：
  名称：

  杂环系列中的药用化学研究。第26次通讯† ‡

  摘要：

  描述了在3-或4-位具有氨基的吡唑并[3,4-d]嘧啶的合成。为了制备3-氨基衍生物，将4-氯-5-氰基-嘧啶与各种肼缩合。4-氨基-吡唑并[3,4-d]嘧啶是通过使3-氨基-4-碳乙氧基-吡唑与甲酰胺反应，氯化4-羟基-吡唑并[3,4-d]嘧啶并取代卤素而获得的。通过氨基。一些化合物表现出利尿和心脏活性，另一些则抑制肿瘤的生长。

  DOI：

  10.1002/hlca.19590420318

文献信息

• Heilmittelchemische Studien in der heterocyclischen Reihe. 26. Mitteilung
  作者：P. Schmidt、K. Eichenberger、M. Wilhelm、J. Druey

  DOI：10.1002/hlca.19590420318

  日期：——

  Syntheses of pyrazolo [3,4-d]pyrimidines with an amino group in 3- or 4-position are described. For the preparation of the 3-amino derivatives a 4-chloro-5-cyano-pyrimidine is condensed with various hydrazines. The 4-amino-pyrazolo [3,4-d]pyrimidines are obtained by reacting 3-amino-4-carbethoxy-pyrazoles with formamide, chlorinating thc 4-hydroxy-pyrazolo [3,4-d]pyrimidines, and substituting the halogen

  描述了在3-或4-位具有氨基的吡唑并[3,4-d]嘧啶的合成。为了制备3-氨基衍生物，将4-氯-5-氰基-嘧啶与各种肼缩合。4-氨基-吡唑并[3,4-d]嘧啶是通过使3-氨基-4-碳乙氧基-吡唑与甲酰胺反应，氯化4-羟基-吡唑并[3,4-d]嘧啶并取代卤素而获得的。通过氨基。一些化合物表现出利尿和心脏活性，另一些则抑制肿瘤的生长。
• Small molecule inhibitors of NF-κB inducing kinase
  申请人：Janssen Pharmaceutica NV

  公开号：US11254673B2

  公开（公告）日：2022-02-22

  The present invention relates to compounds that inhibit NIK and pharmaceutical compositions comprising such compounds and methods of using the same. These compounds and pharmaceutical compositions are envisaged to be useful for preventing or treating diseases such as cancer (such as B-cell malignancies including leukemias, lymphomas and myeloma), inflammatory disorders, autoimmune disorders, immunodermatologic disorders such as palmoplantar pustulosis and hidradenitis suppurativa, and metabolic disorders such as obesity and diabetes.

  本发明涉及抑制 NIK 的化合物、含有此类化合物的药物组合物以及使用方法。根据设想，这些化合物和药物组合物可用于预防或治疗癌症（如 B 细胞恶性肿瘤，包括白血病、淋巴瘤和骨髓瘤）、炎症性疾病、自身免疫性疾病、免疫性皮肤病（如掌跖脓疱病和化脓性扁桃体炎）以及代谢性疾病（如肥胖症和糖尿病）等疾病。
• SMALL MOLECULE INHIBITORS OF NF-kB INDUCING KINASE
  申请人：Janssen Pharmaceutica NV

  公开号：US20210300918A1

  公开（公告）日：2021-09-30

  The present invention relates to compounds that inhibit NIK and pharmaceutical compositions comprising such compounds and methods of using the same. These compounds and pharmaceutical compositions are envisaged to be useful for preventing or treating diseases such as cancer (such as B-cell malignancies including leukemias, lymphomas and myeloma), inflammatory disorders, autoimmune disorders, immunodermatologic disorders such as palmoplantar pustulosis and hidradenitis suppurativa, and metabolic disorders such as obesity and diabetes.
• UNIVERSAL TEMPLATE STRANDS FOR ENZYMATIC POLYNUCLEOTIDE SYNTHESIS
  申请人：MICROSOFT TECHNOLOGY LICENSING, LLC

  公开号：US20210340615A1

  公开（公告）日：2021-11-04

  A universal template strand built with universal base analogs is used as a template for polynucleotide synthesis. The universal template strand can hybridize to any sequence of nucleotides. A new polynucleotide is synthesized by using a polymerase to extend a primer hybridized to the universal template strand. Unlike primer extension in polymerase chain reactions, base pairing with nucleotides in the template strand does not specify the sequence of the new polynucleotide. Instead, the sequence of the new polynucleotide is specified by the order of addition of protected nucleotides. After addition of a single species of protected nucleotide, the blocking group is removed and another protected nucleotide is added. The order of nucleotide addition can be varied to create any sequence. After synthesis, the polynucleotide can be dehybridized from the universal template strand. The universal template strand may then be reused to synthesize a different polynucleotide.